A New Possible Neuropathy Drug - Trial starting now.

@joanland you are incorrect. If you will read article from lancer which is a peer reviewed medical journal you will see phase 2 in humans was completed and proved the topical treatment rejuvenated nerves. The FDA has even approved early compassionate use based on phase 2 success in humans.

@bb0753 if the FDA has approved compassionate use why isnt it out yet? Ive tried to contact WinSanTor many times and agreed to pay for the medication and they have never replied. Now its the Montana right to try……someone is shitting the bed here. Sorry to say

@artemis1886 you are wrong. Phase 2 was completed in humans and showed it improved nerve function. Read the Lancet which is a well known medical journal not just a magazine.

@bb0753
Are you referring to WinSanTor ?
Has it been approved for compassionate use?
Thank you

Yes I am. It has been approved for early compassionate use for diabetes induced but they are working on getting it available through Right to Try new law in Montana that would allow for chronic illnesses. It has been shown to also work on other neuropathy list in their patent document. I have linked the patent document. It is long but if you go all the way near end in section [0201] thru [0220] it lists other types of neuropathy successfully treated. https://patents.google.com/patent/WO2020198252A1/en

Disregard we need a delete button.

@bb0753

The Neurotransmission March 2026, Vol. 1

We know it has been quiet. To those who felt we had gone silent, we want to be direct: the last two years have been a fight for survival.

While the "Biotech Bust" and the fallout of COVID-19 were shutting down companies across the industry, we were navigating a landscape that often prioritizes short-term symptom management over long-term solutions. Big Pharma often looks for the "easy" path. We have chosen to go against the grain. We are pursuing a treatment designed to target the underlying biological markers of nerve health - a path that is harder to fund, but one we believe is vital for the 40 million Americans and hundreds of millions globally living with neuropathy. We stayed in the fight because the data told us to.

Scientific Validation: The Lancet Publication

This past year, our mission reached a major milestone. Our Phase 2a clinical data was published in eBioMedicine's The Lancet - one of the most prestigious medical journals in the world.

Click to read the full study: WST-057 Phase 2a Lancet Publication

This is a profound moment of peer-reviewed validation. The study reported objective evidence of increased intraepidermal nerve fiber density (IENFD) in treated patients. While we continue the rigorous work of Phase 3, having this data recognized globally provides the scientific foundation we need to keep moving forward.

Montana’s SB 535 Right to Try

We are choosing the fastest path to reach you - as early as this summer. While we previously explored traditional federal programs, we found they often carry "one-size-fits-all" bottlenecks that aren't ideal for a drug like ours. Because WST-057 is a topical treatment with established safety data, it is the perfect candidate for a more modern, streamlined approach.

We are shifting our focus to Montana’s groundbreaking SB 535 regulation. This "Right to Try 2.0" framework is much more suitable for our mission because it explicitly supports treatments for severely debilitating diseases like peripheral neuropathy, rather than just terminal ones. It allows for Experimental Treatment Centers that prioritize patient autonomy and medical freedom. WinSanTor is proud to be a pioneer in this program, and we are collaborating with state officials to help establish the operational framework that will allow eligible patients - from anywhere in the world - to travel to Montana to seek access to WST-057.

This renewed optimism is bolstered by a shifting tide in Washington. The current administration (FDA/HHS) has signaled a move toward "modernizing biology" and cutting the red tape that has historically stalled progress for debilitating diseases. With leadership focused on clearing paths for breakthrough treatments, the alignment between state-level freedom and federal flexibility is exactly what a drug like ours needs to move forward.
Sign Up for our Right to Try Progam
How to Get Ready: Your Checklist for Access

To prepare for the launch of the Montana program and potential expansions into other Right to Try states, please follow these three steps:

Coordinate with Your Physician: Your treating doctor must certify that you have a severely debilitating condition and have considered standard options. Share The Lancet publication with them; it provides the peer-reviewed evidence they need to support your request.
Verify Your Eligibility: Under the Montana framework, patients must provide informed consent and acknowledge the experimental nature of the treatment. This is a program for those seeking to address the underlying disease, not just manage pain.
Prepare for Travel: Montana’s program requires your physical presence at a licensed Experimental Treatment Center. Start considering the logistics of travel now. We are also working to bring similar programs to other regions for those who cannot travel to Montana.

Join the Mission

We’ve survived the "biotech winter," and now we need this community to be as proactive as we are. You have a voice that the industry cannot ignore. We are asking you to do one thing today that costs $0 but builds massive momentum:

Tell 5 people about the pioneering Montana Access Pathway
Forward this email to 5 people you know who are seeking new options.
Share our Sign-Up Link in your support groups.
Tell your physician about the Montana framework and our publication in The Lancet.

When you share this, you help us demonstrate the massive, global demand for new pathways in nerve health. That "patient power" is what helps us secure the remaining resources to finish our Phase 3 journey.

Thank you for standing with us. We are the underdog, we have the data, and with your voice, we have a clear path forward.
Warm regards,
The WinSanTor Team

This is for diabetics only mine is caused by several autoimmune disorders. That’s were my frustration lays there are no studies for those of us that have autoimmune neuropathy and it’s moved into my heart so a cream would not help people like me.

@megidigo I'm 76 years old had neuropathy for several years I've had Gabapentin I'm on pregabalin I am looking all around myself trying different things trying to eat better I have type 2 diabetes I never heard of what you're talking about but I'm going to look into it it is pretty scary when you don't know and no one can tell you what's going to happen and how long I pray for you God bless you

Know of compound pharmacy offering :

Phase 2b clinical trials have evaluated the safety and efficacy of 4% pirenzepine in patients, investigating its effect on reducing pain and improving nerve density.